CO2019003178A2 - Compuestos de dinucleótidos cíclicos - Google Patents
Compuestos de dinucleótidos cíclicosInfo
- Publication number
- CO2019003178A2 CO2019003178A2 CONC2019/0003178A CO2019003178A CO2019003178A2 CO 2019003178 A2 CO2019003178 A2 CO 2019003178A2 CO 2019003178 A CO2019003178 A CO 2019003178A CO 2019003178 A2 CO2019003178 A2 CO 2019003178A2
- Authority
- CO
- Colombia
- Prior art keywords
- cyclic dinucleotide
- dinucleotide compounds
- compounds
- cyclic
- groups
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención se refiere a compuestos de la fórmula general (I), (I), en donde los grupos R1, R2 y R3 se definen como en la reivindicación 1, que tiene propiedades farmacológicas valiosas, en particular son moduladores de STING.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16191919 | 2016-09-30 | ||
| PCT/EP2017/074608 WO2018060323A1 (en) | 2016-09-30 | 2017-09-28 | Cyclic dinucleotide compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2019003178A2 true CO2019003178A2 (es) | 2019-04-12 |
Family
ID=57103851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2019/0003178A CO2019003178A2 (es) | 2016-09-30 | 2019-03-29 | Compuestos de dinucleótidos cíclicos |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US10537590B2 (es) |
| EP (1) | EP3519420B1 (es) |
| JP (1) | JP6509445B2 (es) |
| KR (2) | KR20220084206A (es) |
| CN (1) | CN109843903B (es) |
| AR (1) | AR109777A1 (es) |
| AU (1) | AU2017333933B2 (es) |
| CA (1) | CA3038860C (es) |
| CL (1) | CL2019000775A1 (es) |
| CO (1) | CO2019003178A2 (es) |
| CY (1) | CY1124638T1 (es) |
| DK (1) | DK3519420T3 (es) |
| EA (1) | EA037030B1 (es) |
| ES (1) | ES2848724T3 (es) |
| HR (1) | HRP20210027T1 (es) |
| HU (1) | HUE053819T2 (es) |
| IL (1) | IL265642B (es) |
| JO (1) | JOP20190066B1 (es) |
| LT (1) | LT3519420T (es) |
| MA (1) | MA46325B1 (es) |
| MX (1) | MX2019003586A (es) |
| MY (1) | MY200083A (es) |
| NZ (1) | NZ750906A (es) |
| PE (1) | PE20191503A1 (es) |
| PH (1) | PH12019500706B1 (es) |
| PL (1) | PL3519420T4 (es) |
| PT (1) | PT3519420T (es) |
| RS (1) | RS61423B1 (es) |
| SA (1) | SA519401435B1 (es) |
| SI (1) | SI3519420T1 (es) |
| TW (1) | TWI774697B (es) |
| UA (1) | UA124347C2 (es) |
| WO (1) | WO2018060323A1 (es) |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ746112A (en) | 2016-03-18 | 2023-01-27 | Immune Sensor Llc | Cyclic di-nucleotide compounds and methods of use |
| US11098077B2 (en) | 2016-07-05 | 2021-08-24 | Chinook Therapeutics, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
| KR20230010826A (ko) | 2016-10-14 | 2023-01-19 | 프리시젼 바이오사이언시스 인코포레이티드 | B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제 |
| JOP20170192A1 (ar) | 2016-12-01 | 2019-01-30 | Takeda Pharmaceuticals Co | داي نوكليوتيد حلقي |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| US20200055883A1 (en) | 2017-02-17 | 2020-02-20 | Eisai R&D Management Co., Ltd. | Cyclic di-nucleotides derivative for the treatment of cancer |
| SG11201908813QA (en) | 2017-04-13 | 2019-10-30 | Aduro Biotech Holdings Europe B V | Anti-sirp alpha antibodies |
| EP3612181A4 (en) | 2017-04-21 | 2021-01-06 | Epizyme, Inc. | Combination therapies with ehmt2 inhibitors |
| CN111263767B (zh) | 2017-08-30 | 2023-07-18 | 北京轩义医药科技有限公司 | 作为干扰素基因调节剂的刺激剂的环状二核苷酸 |
| WO2019084060A1 (en) | 2017-10-24 | 2019-05-02 | Silverback Therapeutics, Inc. | CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS |
| CN111566119A (zh) | 2017-11-10 | 2020-08-21 | 武田药品工业有限公司 | Sting调节剂化合物以及制备和使用方法 |
| US10966999B2 (en) | 2017-12-20 | 2021-04-06 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| CN111511754B (zh) | 2017-12-20 | 2023-09-12 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸 |
| US12220462B1 (en) | 2018-02-13 | 2025-02-11 | Abionyx Pharma Sa | Complexes for delivery of cyclic dinucleotides |
| CA3091142C (en) | 2018-02-26 | 2023-04-11 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
| JP2021519279A (ja) * | 2018-03-27 | 2021-08-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 修飾環式ジヌクレオチド化合物 |
| US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
| ES2929415T3 (es) | 2018-05-25 | 2022-11-29 | Incyte Corp | Compuestos heterocíclicos tricíclicos como activadores de STING |
| WO2020028566A1 (en) | 2018-07-31 | 2020-02-06 | Incyte Corporation | Heteroaryl amide compounds as sting activators |
| WO2020028565A1 (en) | 2018-07-31 | 2020-02-06 | Incyte Corporation | Tricyclic heteraryl compounds as sting activators |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| MX2020013322A (es) | 2018-08-16 | 2021-02-22 | Eisai R&D Man Co Ltd | Sales de compuestos y cristales de los mismos. |
| KR102567590B1 (ko) | 2018-09-06 | 2023-08-17 | 다이이찌 산쿄 가부시키가이샤 | 신규 고리형 디뉴클레오티드 유도체 및 그 항체 약물 콘쥬게이트 |
| AU2019339344A1 (en) | 2018-09-12 | 2021-03-18 | Silverback Therapeutics, Inc. | Compositions for the treatment of disease with immune stimulatory conjugates |
| KR102755652B1 (ko) | 2018-09-21 | 2025-01-21 | 상하이 드 노보 파마테크 컴퍼니 리미티드 | 고리형 디뉴클레오티드 유사체, 이의 약학 조성물 및 용도 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| US11110106B2 (en) | 2018-10-29 | 2021-09-07 | Venenum Biodesign, LLC | Sting agonists for treating bladder cancer and solid tumors |
| AU2019371206A1 (en) | 2018-10-29 | 2021-05-27 | Venenum Biodesign, LLC | Novel sting agonists |
| MX2021005047A (es) | 2018-10-31 | 2021-09-08 | Gilead Sciences Inc | Compuestos de 6-azabenzimidazol sustituidos como inhibidores de hpk1. |
| CN117105933A (zh) | 2018-10-31 | 2023-11-24 | 吉利德科学公司 | 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物 |
| US11596692B1 (en) | 2018-11-21 | 2023-03-07 | Incyte Corporation | PD-L1/STING conjugates and methods of use |
| WO2020146237A1 (en) | 2019-01-07 | 2020-07-16 | Incyte Corporation | Heteroaryl amide compounds as sting activators |
| DK3934757T3 (da) | 2019-03-07 | 2023-04-17 | Inst Of Organic Chemistry And Biochemistry Ascr V V I | 2'3'-cykliske dinukleotider og prodrugs deraf |
| AU2020231115B2 (en) | 2019-03-07 | 2025-02-20 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| US11766447B2 (en) | 2019-03-07 | 2023-09-26 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| JP7621974B2 (ja) | 2019-05-09 | 2025-01-27 | アリゴス セラピューティクス インコーポレイテッド | Ｓｔｉｎｇモジュレータとしての修飾環状ジヌクレオシド化合物 |
| IL287938B2 (en) | 2019-05-10 | 2025-07-01 | Takeda Pharmaceuticals Co | Antibody-drug conjugates |
| TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
| PE20220231A1 (es) | 2019-06-25 | 2022-02-07 | Gilead Sciences Inc | Proteinas de fusion flt3l-fc y metodos de uso |
| AU2020310853A1 (en) | 2019-07-05 | 2022-01-27 | Tambo, Inc. | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
| US20220296619A1 (en) | 2019-08-19 | 2022-09-22 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| EP4458975A3 (en) | 2019-09-30 | 2025-02-12 | Gilead Sciences, Inc. | Hbv vaccines and methods treating hbv |
| CA3151322A1 (en) | 2019-10-01 | 2021-04-08 | Silverback Therapeutics, Inc. | Combination therapy with immune stimulatory conjugates |
| EP4069729B1 (en) | 2019-12-06 | 2025-01-22 | Precision BioSciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
| US11179473B2 (en) | 2020-02-21 | 2021-11-23 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
| BR112022015283A2 (pt) | 2020-03-06 | 2022-09-20 | Daiichi Sankyo Co Ltd | Conjugado anticorpo-fármaco incluindo derivados de dinucleotídeos cíclicos |
| AR121620A1 (es) | 2020-03-20 | 2022-06-22 | Gilead Sciences Inc | Profármacos de nucleósidos 4-c-sustituidos-2-halo-2-deoxiadenosina y métodos de preparación y uso de los mismos |
| TW202200136A (zh) | 2020-04-10 | 2022-01-01 | 日商小野藥品工業股份有限公司 | 癌治療方法 |
| WO2021236658A1 (en) | 2020-05-19 | 2021-11-25 | Boehringer Ingelheim International Gmbh | Binding molecules for the treatment of cancer |
| CN116209678A (zh) | 2020-07-01 | 2023-06-02 | 安尔士制药公司 | 抗asgr1抗体缀合物及其用途 |
| WO2022032191A1 (en) | 2020-08-07 | 2022-02-10 | Tambo, Inc. | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
| US12110305B2 (en) | 2020-08-07 | 2024-10-08 | Gilead Sciences, Inc. | Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use |
| KR20230061360A (ko) | 2020-09-02 | 2023-05-08 | 다이이찌 산쿄 가부시키가이샤 | 신규 엔도-β-N-아세틸글루코사미니다아제 |
| WO2022079175A1 (en) | 2020-10-14 | 2022-04-21 | Boehringer Ingelheim International Gmbh | Combination of a sting agonist and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist |
| AU2021363267A1 (en) | 2020-10-20 | 2023-06-22 | Tyligand Bioscience (Shanghai) Limited | Multifunctional cyclic dinucleotide and use thereof |
| EP4240488A1 (en) | 2020-11-09 | 2023-09-13 | Takeda Pharmaceutical Company Limited | Antibody drug conjugates |
| TW202241454A (zh) | 2021-02-01 | 2022-11-01 | 日商第一三共股份有限公司 | 抗體－免疫賦活化劑共軛物之新穎製造方法 |
| AU2022274607A1 (en) | 2021-05-13 | 2023-11-16 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
| US20220389394A1 (en) | 2021-05-18 | 2022-12-08 | Gilead Sciences, Inc. | METHODS OF USING FLT3L-Fc FUSION PROTEINS |
| JP7686086B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリエルコール（ｄｉａｃｙｌｇｌｙｅｒｃｏｌ）キナーゼ調節化合物 |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| TW202346322A (zh) | 2022-03-02 | 2023-12-01 | 日商第一三共股份有限公司 | 含Ｆｃ分子之製造方法 |
| EP4582106A1 (en) | 2022-08-29 | 2025-07-09 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate including mutant fc region |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240243A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus |
| CN119930724B (zh) * | 2024-12-18 | 2025-10-28 | 湖南大学 | 一种诱导激活的自递送环二核苷衍生物及其制备方法与用于抗肿瘤免疫治疗的用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE478886T1 (de) | 2003-07-25 | 2010-09-15 | Idenix Pharmaceuticals Inc | Purin nucleoside für die behandlung von durch flavividrae verursachten krankheiten, einschliesslich hepatitis c |
| CA2560058C (en) * | 2004-03-15 | 2011-10-18 | David K.R. Karaolis | A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis |
| US7592326B2 (en) | 2004-03-15 | 2009-09-22 | Karaolis David K R | Method for stimulating the immune, inflammatory or neuroprotective response |
| CA2735006A1 (en) | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Pd-1 antagonists and methods of use thereof |
| US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
| CA2804550C (en) | 2010-07-09 | 2021-01-05 | Bionovion Holding B.V. | Agonistic antibody to cd27 |
| AU2013358892B2 (en) | 2012-12-13 | 2018-06-21 | Aduro Biotech, Inc. | Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use |
| KR102255996B1 (ko) | 2012-12-19 | 2021-05-26 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 포유동물 시클릭 디-뉴클레오티드 신호 경로의 약학적 표적화 |
| ES2822584T3 (es) | 2013-05-03 | 2021-05-04 | Univ California | Inducción de dinucleótidos cíclicos del interferón tipo I |
| PE20160080A1 (es) | 2013-05-18 | 2016-02-21 | Aduro Biotech Inc | Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon |
| WO2015017652A1 (en) | 2013-07-31 | 2015-02-05 | Memorial Sloan-Kettering Cancer Center | Sting crystals and modulators |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| ME03558B (me) | 2014-03-14 | 2020-07-20 | Novartis Ag | Molekuli anti-lag-3 antiтela i njihove upotrebe |
| JP6462006B2 (ja) | 2014-06-04 | 2019-01-30 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｓｔｉｎｇのモジュレーターとしての環式ジヌクレオチド |
| CN107148424B (zh) | 2014-12-16 | 2021-01-08 | 凯拉治疗股份公司 | 用于诱导细胞因子的环状二核苷酸 |
| GB201501462D0 (en) | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| US10449211B2 (en) | 2015-03-10 | 2019-10-22 | Aduro Biotech, Inc. | Compositions and methods for activating “stimulator of interferon gene”—dependent signalling |
| EA034786B1 (ru) | 2015-08-13 | 2020-03-20 | Мерк Шарп И Доум Корп. | Циклические динуклеотидные соединения в качестве агонистов sting |
-
2017
- 2017-09-27 US US15/716,720 patent/US10537590B2/en active Active
- 2017-09-28 WO PCT/EP2017/074608 patent/WO2018060323A1/en not_active Ceased
- 2017-09-28 UA UAA201904428A patent/UA124347C2/uk unknown
- 2017-09-28 MX MX2019003586A patent/MX2019003586A/es unknown
- 2017-09-28 RS RS20210104A patent/RS61423B1/sr unknown
- 2017-09-28 EA EA201990785A patent/EA037030B1/ru not_active IP Right Cessation
- 2017-09-28 PT PT177727310T patent/PT3519420T/pt unknown
- 2017-09-28 AU AU2017333933A patent/AU2017333933B2/en active Active
- 2017-09-28 EP EP17772731.0A patent/EP3519420B1/en active Active
- 2017-09-28 MY MYPI2019000587A patent/MY200083A/en unknown
- 2017-09-28 PL PL17772731T patent/PL3519420T4/pl unknown
- 2017-09-28 SI SI201730631T patent/SI3519420T1/sl unknown
- 2017-09-28 JO JOP/2019/0066A patent/JOP20190066B1/ar active
- 2017-09-28 PE PE2019000722A patent/PE20191503A1/es unknown
- 2017-09-28 ES ES17772731T patent/ES2848724T3/es active Active
- 2017-09-28 HU HUE17772731A patent/HUE053819T2/hu unknown
- 2017-09-28 NZ NZ750906A patent/NZ750906A/en unknown
- 2017-09-28 MA MA46325A patent/MA46325B1/fr unknown
- 2017-09-28 HR HRP20210027TT patent/HRP20210027T1/hr unknown
- 2017-09-28 JP JP2018530574A patent/JP6509445B2/ja active Active
- 2017-09-28 LT LTEP17772731.0T patent/LT3519420T/lt unknown
- 2017-09-28 PH PH1/2019/500706A patent/PH12019500706B1/en unknown
- 2017-09-28 KR KR1020227019917A patent/KR20220084206A/ko not_active Withdrawn
- 2017-09-28 CN CN201780064246.7A patent/CN109843903B/zh active Active
- 2017-09-28 KR KR1020197012683A patent/KR102536447B1/ko active Active
- 2017-09-28 DK DK17772731.0T patent/DK3519420T3/da active
- 2017-09-28 CA CA3038860A patent/CA3038860C/en active Active
- 2017-09-29 AR ARP170102737A patent/AR109777A1/es not_active Application Discontinuation
- 2017-09-29 TW TW106133691A patent/TWI774697B/zh active
-
2019
- 2019-03-25 CL CL2019000775A patent/CL2019000775A1/es unknown
- 2019-03-26 IL IL265642A patent/IL265642B/en unknown
- 2019-03-27 SA SA519401435A patent/SA519401435B1/ar unknown
- 2019-03-29 CO CONC2019/0003178A patent/CO2019003178A2/es unknown
-
2021
- 2021-02-08 CY CY20211100105T patent/CY1124638T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019003178A2 (es) | Compuestos de dinucleótidos cíclicos | |
| CO2019009365A2 (es) | Anticuerpos anti-lag3 | |
| CL2019002590A1 (es) | Compuestos de dinucleótidos cíclicos modificados. | |
| CL2018003323A1 (es) | Piridinas sustituidas con heteroarilo y métodos de uso. | |
| UY35908A (es) | Moduladores de tetrahidropiridopirazinas de gpr6 | |
| CO2017013709A2 (es) | Lactamas bicíclicas. | |
| CL2018000786A1 (es) | Nuevos derivados de pirrolo[2,3-d]pirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen. | |
| MX2019007750A (es) | Moléculas guía sintéticas, composiciones y métodos relacionados con éstas. | |
| CO2018006662A2 (es) | Agonistas del receptor de apelina y métodos de uso | |
| BR112018006471A2 (pt) | compostos úteis como moduladores de trpm8 | |
| CL2018000953A1 (es) | 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj) | |
| DOP2017000298A (es) | Reguladores de nrf2 | |
| CU24408B1 (es) | Compuestos de dihidroisoquinolinona sustituida | |
| CO2017008600A2 (es) | Análogos de desacetoxitubulisina h, composiciones y método de producción de los mismos | |
| UY35305A (es) | Compuestos sustituidos como moduladores de la pro teína de activación de la 5-lipoxigenasa (flap) | |
| MX2017011821A (es) | Silanos y composiciones curables que contienen dichos silanos como reticulantes. | |
| AR104174A1 (es) | Oxadiazoles sustituidos con deuterio | |
| MA38982A1 (fr) | Nouvel octahydro-cyclobuta [1,2-c; 3,4-c'] dipyrrol-2-yl | |
| BR112014030474A2 (pt) | novos compostos bicíclicos de tiofenilamida | |
| MX2020007565A (es) | Nuevos oxadiazoles. | |
| BR112017023338A2 (pt) | composição polimérica reforçada com fibra, e, artigo. | |
| CR20160448A (es) | Nuevos derivados de piridina | |
| DOP2016000211A (es) | Pirazinas moduladoras de gpr6 | |
| CU24420B1 (es) | Derivados de diheterociclo enlazado a cicloalquilo | |
| MX2018008776A (es) | Composiciones que contienen carbodiimida polimerica, epoxido y polimeros a base de poliester, su produccion y uso. |